Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery

NCT03735680 is registered in ClinicalTrials.gov with OncoNano Medicine, Inc. as lead sponsor.

NCT NCT03735680
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03735680 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance, Safety & Timing of Postdose Imaging of ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Solid Tumors Undergoing Routine Surgery
Lead sponsor
OncoNano Medicine, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 9, 2019
Completion date
November 18, 2021
Enrollment
30 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, prostate cancer, urothelial carcinoma